Cerevel Therapeutics/CERE

$42.21

0.07%
-
1D1W1MYTD1YMAX

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

Ticker

CERE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

N. Coles

Employees

334

Headquarters

Cambridge, United States

CERE Metrics

BasicAdvanced
$7.55B
Market cap
-
P/E ratio
-$2.66
EPS
1.48
Beta
-
Dividend rate
$7.55B
1.48433
$43.59
$19.59
1.46M
10.924
50.082
50.082
-38.29%
-72.44%
-41.29%
11.198
11.211
-14.64%

What the Analysts think about CERE

Analyst Ratings

Majority rating from 9 analysts.
Hold

Price Targets

Average projection from 10 analysts.
2.82% upside
High $45.00
Low $31.00
$42.21
Current price
$43.40
Average price target

CERE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-132.6M
37.69%
Profit margin
0%
-

CERE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 27.75%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.67
-$0.63
-$0.61
-$0.76
-
Expected
-$0.67
-$0.65
-$0.63
-$0.59
-$0.61
Surprise
-0.65%
-2.86%
-3.51%
27.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cerevel Therapeutics stock?

Cerevel Therapeutics (CERE) has a market cap of $7.55B as of April 20, 2024.

What is the P/E ratio for Cerevel Therapeutics stock?

The price to earnings (P/E) ratio for Cerevel Therapeutics (CERE) stock is 0 as of April 20, 2024.

Does Cerevel Therapeutics stock pay dividends?

No, Cerevel Therapeutics (CERE) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Cerevel Therapeutics dividend payment date?

Cerevel Therapeutics (CERE) stock does not pay dividends to its shareholders.

What is the beta indicator for Cerevel Therapeutics?

Cerevel Therapeutics (CERE) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cerevel Therapeutics stock price target?

The target price for Cerevel Therapeutics (CERE) stock is $43.4, which is 2.82% above the current price of $42.21. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cerevel Therapeutics stock

Buy or sell Cerevel Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing